A carregar...
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an “undruggable” target due to the lack of deep binding pockets for specific small-molecule inhibitors. A better understanding of the mechanisms that drive KRAS transfor...
Na minha lista:
| Publicado no: | Cell Rep Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7817862/ https://ncbi.nlm.nih.gov/pubmed/33521700 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xcrm.2020.100186 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|